NVS

Business Context and Reporting Period

Company: Novartis AG
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2000
Accounting Standards: International Accounting Standards (IAS) with U.S. GAAP reconciliation provided.
Key Event: The Agribusiness sector (Crop Protection and Seeds) was spun off and merged with AstraZeneca's Zeneca Agrochemicals to form Syngenta AG on November 6, 2000. Consequently, Agribusiness is reported as a discontinuing activity.

Key Financial Metrics (Year Ended Dec 31, 2000)

Note: USD figures are translated at the rate of CHF 1.64 = $1.00.

Material Changes vs. Prior Period

• Revenue Growth: Total Group sales increased 10% to CHF 35.8 billion. Sales from continuing operations grew 15% to CHF 29.1 billion, driven by a 7% favorable currency effect and 6% volume growth.
• Profitability: Operating income from continuing activities grew 6% to CHF 6.7 billion. However, the operating margin for continuing activities decreased from 25.1% in 1999 to 23.1% in 2000.
• Expense Increases: Marketing and distribution expenses rose sharply by 23% (to 33% of sales) to support new product launches. Administration and general overheads increased 34% due to one-time items including the PPA product recall (CHF 84 million) and Wesley Jessen integration costs (CHF 41 million).
• Segment Performance:
  • Pharmaceuticals: Sales up 15%; Operating income up 16% to CHF 5.4 billion. Margin maintained at 31%.
  • Generics: Sales up 6%; Operating income down 35% to CHF 227 million due to price erosion in the U.S. and increased R&D.
  • CIBA Vision: Sales up 28%; Operating income down 37% to CHF 158 million, impacted by CHF 110 million in one-time acquisition integration costs.
  • Consumer Health: Sales up 15%; Operating income up 2% to CHF 824 million, despite a CHF 84 million charge for the PPA recall.
• Acquisitions: Significant acquisitions included Wesley Jessen VisionCare (CHF 1.3 billion) and antiviral products Famvir/Vectavir from SmithKline Beecham (CHF 2.7 billion).

Guidance, Outlook, and Risks

Outlook and Guidance:

• Management expects to launch five new products in 2001, including Starlix (diabetes), Zometa (hypercalcemia), Zelmac (IBS), Xolair (asthma), and Glivec (leukemia).
• Marketing and sales investments for new launches are expected to increase by an extra CHF 1 billion in 2001.
• Pharmaceuticals operating margin is expected to contract by approximately 2% in the near term due to these investments, with an additional 1% reduction due to the transfer of the Ophthalmics business unit from CIBA Vision.
• Generics and CIBA Vision are expected to achieve significant growth in the coming year.

Key Risks and Contingencies:

• Patent Expirations: Loss of patent protection for key products (Neoral, Aredia, Sandostatin, Cibacen) is expected to lead to generic competition and sales declines. The company is relying on follow-up drugs (e.g., Zometa, Lotrel) to offset erosion.
• Regulatory and Pricing Pressure: Intense price controls in the U.S., EU, and Japan, along with potential Medicare reform, pose risks to revenue. Regulatory delays in product approvals are also a significant risk.
• Product Liability and Environmental: The company faces ongoing product liability claims and environmental remediation obligations, though management believes accrued provisions are adequate.
• Foreign Exchange: Significant exposure to currency fluctuations (44% of sales in USD, 24% in Euro) impacts reported earnings.

Investor Verification Checklist

• Discontinued Operations: Verify the separation of Agribusiness results (Syngenta spin-off) to accurately assess the performance of the core healthcare business.
• One-Time Charges: Review the impact of the CHF 84 million PPA recall and CHF 110 million Wesley Jessen integration costs on the true operating margin of Consumer Health and CIBA Vision.
• Patent Cliff: Assess the timeline for generic entry for Neoral, Aredia, and Sandostatin and the commercial success of replacement products like Zometa and Lotrel.
• U.S. GAAP Reconciliation: Note the significant differences between IAS and U.S. GAAP, particularly regarding purchase accounting for the 1996 merger, stock-based compensation, and pension provisions, which reduce reported net income under U.S. GAAP.
• Debt Reduction: Confirm the improvement in the debt-to-equity ratio (0.16:1 in 2000 vs 0.27:1 in 1999) following the transfer of debt to Syngenta and debt repayments.